Indivumed Services

November is Lung Cancer Awareness Month.🫁 During this month, we'll focus on highlighting key research and developments to raise awareness about this critical health issue. Lung cancer is the most common cancer worldwide, it's the leading cancer in men and the second most common in women.¹ There are two main forms of lung cancer - small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer (NSCLC) is the more common form of the disease, accounting for about 80% of diagnosed cases.² Our recent study explores how combining spatial transcriptomics with bulk RNA-Seq data can drive insights into NSCLC. This was done in collaboration with the Advanced Analytics and AI department at Indivumed Therapeutics and was previously presented at ESMO Congress in 2023. Read the research https://hubs.la/Q02WDH2G0 #LungCancer #LungCancerAwareness #CancerResearch #NSCLC #HealthAwareness ¹https://hubs.la/Q02WDHlf0 ² https://hubs.la/Q02WDLmM0

🎗️Beating Breast Cancer Twice: Why our mission of ensuring that every patient gets the right treatment at the right time means so much to Nalini.🎗️ To mark the end of #BreastCancerAwarenessMonth, we are privileged to share Nalini Murdter's commitment to cancer research and treatment. Below is her personal story – inspiring us with every word. "As the President of Indivumed, a Crown Bioscience company, and a two-time cancer survivor, my perspective on personalized cancer treatment has been profoundly shaped by both professional expertise and personal experience. My personal principle is to remain stoic and focus on what I can control while finding meaning in adversity. My journey exemplifies this approach. ➡️Fighting Cancer with stoic resolve When first diagnosed with breast cancer 16 years ago, I approached it not with fear, but with scientific curiosity. This detached observation allowed me to gain valuable insights into the treatment process. A severe drug reaction during treatment highlighted a critical gap in oncology treatment and the need for more personalized approaches. Fifteen years later, facing a second diagnosis, I confronted my mortality with stoic acceptance. Rather than despair, I channeled my energy into how I could contribute to improving cancer care. ➡️Turning Adversity into Purpose My experiences revealed the limitations of one-size-fits-all treatments. The discovery of my taxane allergy during the second treatment underscored the importance of tailored approaches. These challenges became opportunities to contribute to improving cancer care from diagnosis to treatment and beyond. ➡️Advancing Personalized Medicine At Indivumed Services, Crown Bioscience and JSR Life Sciences we're at the forefront of personalized cancer treatment. Our work with our customers and partners, aims to ensure that each patient receives the most effective treatment based on their unique cancer profile, minimizing adverse reactions and improving outcomes. ➡️Using Adversity to Guide Leadership Principles My experiences have impacted my leadership style: I face challenges with equanimity and see setbacks as opportunities for growth and innovation. This is also how I guide my team to pursue their responsibilities. By combining cutting-edge science with a deeply personal understanding of the patient experience, I work with my team and my colleagues to drive our contributions toward an improved era of personalized cancer care. Our goal is to ensure that future patients benefit from truly individualized treatments, improving both survival rates and their quality of life. #CancerResearch #Biomarkers

Every minute matters in cancer research!⏱️ Did you know that biological changes in tissues can begin in just 15 minutes after extraction? This can significantly impact cold ischemic time and compromise critical biomolecules like proteins and RNA. At Indivumed Services, we prioritize a controlled, standardized approach to sample collection. Our globally standardized SOP-driven process ensures the highest quality samples for your research. With over 20 years of experience, we are committed to minimizing ischemia times and delivering standardized sample preparation. Learn more ➡️ https://hubs.la/Q02W8ylC0

We're here at Biomarkers US 2024 at booth 11 from 28-29th October! Meet us to discuss our innovative technologies and approaches for biomarker validation & identification, biomarker analysis, and applications in precision oncology! Don't miss the opportunity to connect with Steven Feckley, Julie Ann Mayer, PhD, Sherr Aquino, Sadaf M., and Yan Han to explore how we can collaborate to drive innovation. Precision Medicine by Oxford Global Indivumed Services

Meet us at ENA 2024, Booth 18. Crown Bioscience & Indivumed Services

📢We are now offering the cutting-edge Visium HD assay on the CytAssist platform from 10x Genomics, marking a significant advancement in spatial transcriptomics! As a Certified Service Provider of 10x Genomics since 2021, and with extensive experience in tissue handling and processing, we provide a comprehensive end-to-end solution for your Spatial Transcriptomics projects. The powerful CytAssist-enabled assays streamline the workflow, enabling researchers to obtain spatially resolved gene expression data more efficiently. With the latest Visium HD, you can now achieve: ✅ Whole transcriptome spatial analysis at single-cell scale ✅ Continuous tissue coverage - no gaps! ✅ FFPE, FF tissue ✅ Best-in-class data quality Discover more and contact us today! https://hubs.la/Q02VsSM-0

Research is challenging, sourcing you biospecimens shouldn’t be. Our online tool enables you to choose your samples in a streamlined process, allowing you to identify the best matches for your research needs with ease. Just input your criteria and get started with a personalized quote. Choose your samples online today! ➡️ https://hubs.la/Q02TqDsn0

We encourage you to reach out to Sadaf M. to discover how our comprehensive solutions, from sample collection to integrated readouts, can address your oncology research needs. Reach out to us before the event or at any time to advance your next discovery with our unrivaled biospecimen collection. https://lnkd.in/eixsUrXe We look forward to seeing you in San Diego!

Poor tissue or block quality, insufficient tumor cell content, or high levels of necrosis often plague research and development efforts. But with our high-quality specimens and unparalleled clinical expertise, you get to market faster - without compromise. Our expertise is backed by SOP guidance and ISO 9001 certification, ensuring strict quality control and rapid processing of tissue, liquids, and validated clinical data. We offer comprehensive cancer biospecimen sets (FFPE/FF), including normal adjacent tissue, matched plasma and serum (including Streck collections), and matched PBMCs. Researchers trust our tissue sample quality and comprehensive data to verify biomarker targets, driver mutations and clinically significant genomic variants. Learn more ➡️ https://hubs.la/Q02TZwCM0

We're continuing to highlight important facts and research for Breast Cancer Awareness Month. Did you know that quality tissue samples are crucial for accurate HER2 status assessment in breast cancer? In this research, breast cancer patient samples sourced from various biobanks were assessed for HER2 (ERBB2) gene amplification and protein overexpression using three different analytical methods. Our high-quality tissues demonstrated the highest concordance rate using the GeneXpert Breast Cancer Biomarker Assay (Xpert BC) and standard methods (IHC and FISH). Download the application note ➡️ https://hubs.la/Q02TGdMR0 #BreastCancerAwarenessMonth #BreastCancer